Bleeding Complications in Oral Anticoagulant Therapy

Meer, M. van der; Rosendaal, F.R.; Vandenbroucke, Jan P.; Bnet, Ernest

doi:10.1001/archinte.1993.00410130073007

Cited by 406 publications

(73 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,4,[7][8][9][10][11][12][13][14][15][16] Although some studies have identified age as a significant risk factor for major hemorrhage, 4,10,11,13,15 other studies have not. 1,[7][8][9]14,16 Fihn et al examined the effect of increasing age on the risk of hemorrhage in a combined retrospective and prospective cohort study. 17 They determined that age was not a strong risk factor for hemorrhage with the possible exception of patients aged 80 years or older.…”

Section: Risk Factorsmentioning

confidence: 99%

Risk of major hemorrhage for outpatients treated with warfarin

et al. 1998

View full text Add to dashboard Cite

OBJECTIVE:To determine the incidence of major hemorrhage among outpatients started on warfarin therapy after the recommendation in 1986 for reduced-intensity anticoagulation therapy was made, and to identify baseline patient characteristics that predict those patients who will have a major hemorrhage. DESIGN:Retrospective cohort study. SETTING:A university-affiliated Veterans Affairs Medical Center. PATIENTS:Five hundred seventy-nine patients who were discharged from the hospital after being started on warfarin therapy. MEASUREMENTS AND MAIN RESULTS:The primary outcome variable was major hemorrhage. In our cohort of 579 patients, there were 40 first-time major hemorrhages with only one fatal bleed. The cumulative incidence was 7% at 1 year. The average monthly incidence of major hemorrhage was 0.82% during the first 3 months of treatment and decreased to 0.36% thereafter. Three independent predictors of major hemorrhage were identified: a history of alcohol abuse, chronic renal insufficiency, and a previous gastrointestinal bleed. Age, comorbidities, medications known to influence prothrombin levels, and baseline laboratory values were not associated with major hemorrhage. CONCLUSIONS:The incidence of major hemorrhage in this population of outpatients treated with warfarin was lower than previous estimates of major hemorrhage measured before the recommendation for reduced-intensity anticoagulation therapy was made, but still higher than estimates reported from clinical trials. Alcohol abuse, chronic renal insufficiency, and a previous gastrointestinal bleed were associated with increased risk of major hemorrhage.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Risk of major hemorrhage for outpatients treated with warfarin

et al. 1998

View full text Add to dashboard Cite

show abstract

“…[11][12][13] Also the risk of anticoagulant-induced bleeding seems to be enhanced in patients with cancer, 9,[14][15][16] although this is not consistently found. 17,18 Little is known about whether the perceived higher risks for recurrent VTE and bleeding during anticoagulation apply to all patients with cancer or to specific groups.…”

Section: Introductionmentioning

confidence: 99%

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis

Prandoni

Lensing²,

Piccioli³

et al. 2002

Blood

1,693

1,211

View full text Add to dashboard Cite

“…Unter effektiver Antikoagulation werden schwerwiegende Blutungen in einer Häufigkeit von 2,3-6,8 pro 100 Patientenjahre in verschiedenen Studien angegeben (Tabelle 3) [15,34,35,[37][38][39]. Die intrakranielle Blutung als gefürchtetste Komplikation unter Antikoagulation wird mit 0,6-0,9 pro 100 Patientenjahre aufgeführt [15,34,35].…”

Section: Risiken Der Antikoagulationunclassified

Orale Antikoagulation bei Herzinsuffizienz

Adam

Böhm

2008

Herz

View full text Add to dashboard Cite

The risk of thromboembolic complications is increased in patients with advanced chronic heart failure and severe left ventricular dysfunction. Accepted indications for oral anticoagulation include patients with a history of thromboembolism, concomitant atrial fibrillation, or venous, arterial or cardiac thrombosis. In other subgroups, the benefit of chronic anticoagulation has not been proven and existing data from uncontrolled nonrandomized, mostly retrospective studies and prospective, randomized controlled studies are conflicting. This article summarizes the available data on the thromboembolic risk and the potential benefit of antithrombotic therapy and attempts to provide current orientation and recommendations for anticoagulant therapy in patients with chronic heart failure and severe left ventricular dysfunction.

show abstract

Bleeding Complications in Oral Anticoagulant Therapy

Cited by 406 publications

References 19 publications

Risk of major hemorrhage for outpatients treated with warfarin

Risk of major hemorrhage for outpatients treated with warfarin

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis

Orale Antikoagulation bei Herzinsuffizienz

Contact Info

Product

Resources

About